Butcher's Broom

Ruscus aculeatus L. sits in Asparagaceae, subfamily Nolinoideae (older books file it in Liliaceae or Ruscaceae). NCBI Taxonomy treats it as taxon 59067. Linnaeus named it in Species Plantarum (1753); IPNI records the name as 540443-1. It is a dioecious, clump-forming evergreen: stiff, striated shoots bear ovate, spine-tipped cladodes that look like holly leaves and are not. True leaves are reduced to scales. Small greenish-white flowers sit in the center of the cladode; female plants may carry a round red berry. The underground organ is a knobby rhizome with fibrous roots—the Ph. Eur. drug (monograph 1847).

Native range is western and southern Europe, the Mediterranean, and east toward the Black Sea and Iran. It tolerates deep woodland shade and also grows on coastal cliffs and in hedgerows. Garden plantings have escaped in places outside that range. Culinary footnote: young spring shoots are eaten in parts of the Mediterranean like thin asparagus. That is food. It is not a ruscogenin tablet.

Do not confuse butcher's broom with Scotch broom (Cytisus scoparius, Fabaceae), a yellow-flowered shrub whose quinolizidine alkaloids include sparteine, or with Spanish broom (Spartium junceum). Those are different genera. Ruscus hypoglossum is a gentler Ruscus with larger, softer cladodes and showy bracts; it is not the Ph. Eur. rhizome monograph. Florist “Ruscus” greens are decorative cladodes, not a standardized extract.

The chemistry that labels care about is steroidal saponins. Intact glycosides include ruscin, ruscoside, and deglucoruscin. Acid or enzymatic hydrolysis yields the sapogenins ruscogenin and neoruscogenin, which are used to standardize extracts. Rhizomes also carry sterols, flavonoids, and the coumarin glucoside esculin—the same coumarin name that shows up in raw horse-chestnut seed, in a different plant. Barbič and colleagues (2013) found that saponins plus esculin reduced thrombin-induced leakiness of cultured endothelial cells. That is a dish, not a stocking replacement.

The English name is a workshop story. Stiff, evergreen shoots were tied into bunches and used to sweep butchers’ chopping blocks. Italian pungitopo and German Mausedorn—“mouse-stinger”—record another use: spiny branches stacked around stored food to keep pests off. Dioscorides-era Mediterranean pharmacy already knew the plant; none of that is a CVI trial.

Nineteenth-century European herbals treated the rhizome as a diuretic and mild laxative and, later, as a vein herb. The chemical turn is mid-twentieth century: spirostanol saponins based on ruscogenin and neoruscogenin were isolated from the underground parts, and French and German phytomedicine built oral extracts for heavy legs and hemorrhoids. German Commission E approved the rhizome in 1991 as supportive therapy for CVI discomfort and hemorrhoid complaints, with a daily target of 7–11 mg total ruscogenin after hydrolysis.

EU herbal law put the same plant on the traditional-use shelf. HMPC adopted a first community monograph in 2008 and revision 1 on 20 November 2018 (published 2019). The indications stayed traditional: minor venous heaviness, and hemorrhoid itch or burn after serious conditions are excluded. The 166-woman Vanscheidt trial was read and not promoted to well-established use. Combination products—Ruscus plus hesperidin methylchalcone plus ascorbic acid—ran a parallel commercial life (Cyclo 3 Fort, Fabroven). Boyle’s 2003 meta-analysis and Kakkos and Allaert’s 2017 review speak to that mix, not to a single-herb capsule.

In the United States the same rhizome is a dietary supplement. MSKCC’s About Herbs page (updated 2023) records small CVI studies, a combination lymphedema trial, diarrhea with Cyclo 3, contact allergy to ruscogenins, and a diabetic ketoacidosis case report. There is no NCCIH consumer monograph and no LiverTox chapter. History here is a vein-herb file that never quite became horse chestnut’s well-established rank.

Ruscogenin and neoruscogenin are steroidal sapogenins, not a single tablet molecule. Experimental work points to venoconstriction with an α-adrenergic flavor: isolated-vein models contract more when Ruscus extract is applied, and α-blockers blunt the response in older pharmacology. That is why people talk about “vein tone.” It is also why stacking this herb with other vasoconstrictor folklore is not a clever home protocol. EMA does not require a clinical mechanism for traditional use and does not claim one.

Anti-inflammatory stories are better sourced in cells and animals than in people. Huang, Kou, Ma and colleagues (J Pharmacol Sci 2008) reported that ruscogenin cut TNF-α-driven ICAM-1 and NF-κB signaling. Facino and colleagues (1995) found saponins and sapogenins from Ruscus, ivy, and horse chestnut inhibited elastase and hyaluronidase—the enzymes blamed for chewing perivascular matrix in venous disease. Barbič 2013 added endothelial barrier effects for rhizome saponins and esculin. Lymphatic-flow claims exist in combination-product literature; they are not a confirmed human Ruscus-only mechanism (MSKCC).

Standardization is hydrolysis arithmetic. Labels often quote milligrams of ruscogenins (neoruscogenin plus ruscogenin after acid or fermentation). Commission E’s 7–11 mg/day is that sum. EMA’s traditional posology is instead listed as milligrams of powdered rhizome or of named dry extracts, not as a ruscogenin milligram on every pack. Two bottles can share a plant and not share an assay.

Heavy legs and minor venous complaints are the traditional indication. EMA: oral rhizome preparations to relieve discomfort and heaviness related to minor venous circulatory disturbances, in adults, and only after the usual red flags are not present. Vanscheidt et al. (Arzneimittelforschung 2002) randomized 166 women with Widmer I–II / CEAP 3–4 CVI to a methanol dry extract (Fagorutin Ruscus) or placebo for twelve weeks. Intent-to-treat analysis (148 women) found a significant drop in the area-under-baseline of leg-volume change, plus ankle and calf circumference and some symptoms (heavy tired legs, tension) versus placebo. EMA’s public summary still called the overall benefit not convincing: women only, short duration, and not enough to leave traditional use. Read both sentences. A positive RCT and a traditional-use rank can sit together.

Combination products are a larger, messier evidence pile. Boyle, Diehm, and Robertson (Int Angiol 2003) meta-analyzed Cyclo 3 Fort trials in CVI. Kakkos and Allaert (Int Angiol 2017, PMID 28225220) pooled ten mostly low-bias RCTs (719 people) of Ruscus extract plus hesperidin methylchalcone plus vitamin C and reported improvements in pain, heaviness, fatigue, swelling sensation, paresthesia, ankle circumference, and leg volume versus placebo. That is a three-ingredient drug. It is not proof that an unlabeled “butcher’s broom” capsule will do the same. Cappelli, Nicora, and Di Perri (1988) is an older Ruscus-extract venous-disease study still cited in clinical summaries; it is small and not a modern CVI program.

Hemorrhoids: EMA traditional use for itching and burning after a doctor has excluded serious disease. MSKCC says evidence is lacking. There is no Ruscus-only hemorrhoid RCT in the HMPC file. Rectal bleeding is a medical visit, not a dose increase.

Lymphedema after breast-cancer treatment: Cluzan et al. (Lymphology 1996) studied Cyclo 3 Fort for secondary upper-limb lymphedema. Combination product, one trial, not a Ruscus-alone protocol, and not a reason to skip compression or oncology follow-up. Constipation, “diuretic,” atherosclerosis, and general “circulation cleanses” are folk or marketing uses without a serious evidence file (MSKCC).

Do not use butcher's broom to skip a vascular work-up, to treat a DVT, or as a food-like daily tonic. Compression, walking, weight, and indicated procedures remain the medical spine for CVI. Horse chestnut is a different saponin story with a stronger EMA rank; stacking both in an unlabeled “vein complex” is how you lose the thread of which plant did what.

EMA traditional oral products (adults), Ph. Eur. rhizome: powdered herbal substance 350 mg three times daily; aqueous dry extract DER 2.5–6.5:1, 150–200 mg per dose, maximum 450 mg/day; ethanolic dry extract DER 5–8.5:1 (ethanol 80% V/V), 86 mg once or twice daily; ethanolic dry extract DER 6–9:1 (ethanol 96% V/V), 45 mg twice daily (leg-heaviness indication). Hemorrhoid traditional posology covers the powder, the water extract, and the 80% ethanol extract on the same milligram schedule; the 96% ethanol extract is listed for indication 1. If symptoms last more than two weeks, see a clinician. No established use under 18.

Dietary supplements: capsules standardized to ruscogenins (Commission E’s 7–11 mg/day is the older German target), tinctures, and “vein blends” with horse chestnut, gotu kola, or citrus bioflavonoids. Quality varies. Look for Ruscus aculeatus rhizome, not “broom herb” and not Cytisus. Combination tablets with hesperidin methylchalcone and vitamin C are a different product class; match the trial if a clinician still wants that mix.

Food: young shoots cooked like asparagus in Mediterranean kitchens. That exposure is not a CVI dose. Florist cladodes and red berries are not tea material. Do not decoct garden plants of unknown identity.

Topical hemorrhoid creams and “vein” gels with ruscogenin exist in some markets. They are not the oral EMA monograph, and they have a small contact-allergy file. Do not put them on broken skin as a science experiment.

EMA’s 2018 monograph listed no known undesirable effects for the specified traditional oral preparations, with the usual “tell a doctor if something happens” line. Commission E already noted rare gastric disorders or nausea. Real-world products are messier than that sentence.

Gastrointestinal: nausea and stomach upset with some extracts. Chronic diarrhea is a documented problem with Cyclo 3 Fort (Thomas-Anterion et al., 1993, and later case series). MSKCC says diarrhea is frequent with that combination and less common with other butcher's-broom formulations. A combination pill’s diarrhea is not automatically a Ruscus-only effect, but it is a reason to read the label.

Skin: allergic contact dermatitis to ruscogenins is published. Ramírez-Hernández and colleagues (Contact Dermatitis 2006) described lesions from a hemorrhoid cream, then a generalized flare after an anti-cellulite product that also contained ruscogenin. A pregnant woman developed a spreading papulo-erythematous eruption and eyelid edema from a vasoconstrictor cream containing butcher's-broom extract (Landa 1990, cited by MSKCC). Stop the cream; do not treat a rash with more “vein gel.”

Metabolic: Sadarmin and Timperley (J Emerg Med 2013) reported diabetic ketoacidosis in a 39-year-old woman five days after taking butcher's broom for mild ankle swelling. MSKCC lists diabetes as a do-not-take. That is a case report, not a trial, and it is still a reason for people with diabetes to keep this herb in the clinician conversation, not the checkout aisle.

Do not use if you are allergic to Ruscus preparations or to ruscogenins. Do not use Scotch broom or Spanish broom as a substitute. Do not use oral traditional products in children or adolescents; EMA says the use has not been established under 18.

EMA: safety in pregnancy and lactation is not established; use is not recommended. The topical-cream pregnancy case is a separate warning against assuming “natural vein cream” is fine in pregnancy. No fertility data.

See a doctor before any vein herb if there is skin inflammation, hard subcutaneous patches, ulcers, sudden swelling of one or both legs, or known cardiac or renal insufficiency (EMA indication-1 warnings). Those can be clots, ulcers, or organ failure. If rectal bleeding occurs, see a doctor (indication 2). Butcher's broom is not a hemorrhoid that bleeds on its own plan.

MSKCC: skip butcher's broom if you have diabetes, given the ketoacidosis report. CVI still needs a diagnosis. This plant is not a treatment for arterial claudication, unworked-up edema, or post-thrombotic ulcers. Compression, wound care, and indicated procedures remain first.

EMA’s traditional monograph lists no reported drug interactions for the specified oral rhizome preparations. That is a regulatory sentence, not a permission to hide the bottle from a pharmacist.

α-adrenergic pharmacology is the theoretical overlap: other stimulants, decongestants, and some blood-pressure regimens. This is not a documented EMA interaction table. It is a reason not to freelance a “circulation stack.”

Anticoagulants: unlike raw horse-chestnut esculin folklore, butcher's broom does not have a clean bleeding-trial file. Esculin is still present in the rhizome chemistry. If you take warfarin, DOACs, or dual antiplatelet therapy, this is a clinician conversation.

Do not mix unlabeled “circulation” blends (horse chestnut plus butcher's broom plus unidentified citrus bioflavonoids) and then blame one plant when the gut or the liver complains. Combination products already confound diarrhea reports and some older vein-tablet hepatotoxicity stories on the horse-chestnut side. Keep the ingredients countable.